Tesamorelin / Ipamorelin.
A dual GH-axis protocol pairing the most clinically established GHRH analog with a clean GH-pulse peptide.
3 mg / 2 mg per mL · single-vial subcutaneous injectablePricing is shown after your free assessment, before you commit.
Free to start. No card required.
Reviewed by Lumora clinical team (Licensed provider network)Mixed evidenceSource: Client-approved product catalog; provider review required
Evidence, regulatory status, and fit vary by medication, formulation, route, and individual history.
Is this for you?
This is for you if
- Patients targeting visceral (deep abdominal) fat
- Patients wanting body recomposition (fat loss with lean-mass preservation)
- Patients with low energy, poor sleep, or slow recovery despite lifestyle effort
- Patients seeking the most clinically established GH-axis combination
This isn't for you if
Tesamorelin can affect glucose regulation; baseline and follow-up metabolic labs are recommended. Not appropriate during pregnancy, breastfeeding, or with active malignancy.
Tesamorelin / Ipamorelin
This combination pairs Tesamorelin — the only FDA-approved GHRH analog and the peptide with the strongest evidence for visceral-fat reduction — with Ipamorelin, a selective ghrelin-receptor peptide that triggers a clean GH pulse without cortisol or appetite effects.
Mechanism and fit.
Tesamorelin keeps the upstream GHRH signal active, particularly during the body's overnight repair window. Ipamorelin layers a clean GH pulse on top of that signal. The result is amplified, more synchronized GH release than either peptide produces alone — translating into stronger effects on visceral fat, lean-mass preservation, sleep depth, and recovery.
Who this is typically for.
- Patients targeting visceral (deep abdominal) fat
- Patients wanting body recomposition (fat loss with lean-mass preservation)
- Patients with low energy, poor sleep, or slow recovery despite lifestyle effort
- Patients seeking the most clinically established GH-axis combination
What patients
most often ask.
How is this different from CJC-1295 / Ipamorelin?
Both pair Ipamorelin with a GHRH-side peptide. Tesamorelin has the strongest clinical evidence — particularly for visceral fat — and is FDA-approved. CJC-1295 is generally milder and more cost-effective for patients whose primary goals are recovery and sleep rather than visceral-fat reduction.
Will it shrink belly fat?
Visceral fat is the specific target of Tesamorelin. Many patients notice a measurable change in abdominal composition at 8–12 weeks; results vary by individual.
Who this is typically for.
These are common fit patterns from the approved catalog. Your provider determines whether treatment is appropriate.
- <ul><li>Patients targeting visceral (deep abdominal) fat</li><li>Patients wanting body recomposition (fat loss with lean-mass preservation)</li><li>Patients with low energy, poor sleep, or slow recovery despite lifestyle effort</li><li>Patients seeking the most clinically established GH-axis combination</li></ul>
How this option
is evaluated.
The plan is provider-determined after reviewing your assessment and safety factors.
- DosingOnce nightly subcutaneously, typically 5 nights on / 2 nights off, 30–60 minutes before bed.
- Typical durationInitial cycle 2–3 months; optimal results typically seen at 8–12 weeks of consistency.
- Safety and eligibilityYour provider reviews contraindications, medication interactions, goals, and safety factors before prescribing.
- A licensed provider reviews your assessment before any treatment is recommended.
- You see full pricing - visit fees, medication, labs, follow-up - before you commit.
- Your plan can be adjusted, paused, or stopped based on response and safety. Your clinician is reachable - not a chatbot.
- Compounded medications are not FDA-approved and are dispensed only when prescribed by a licensed provider.
Start with
provider review.
If you are considering Tesamorelin / Ipamorelin, the first step is a free assessment. A provider determines whether it fits your goals and medical history.
A provider determines whether treatment is clinically appropriate.